Search Results - "Robertson, Derrick S."

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study by Bar-Or, Amit, Calkwood, Jonathan C., Chognot, Cathy, Evershed, Joanna, Fox, Edward J., Herman, Ann, Manfrini, Marianna, McNamara, John, Robertson, Derrick S., Stokmaier, Daniela, Wendt, Jeanette K., Winthrop, Kevin L., Traboulsee, Anthony

“…OBJECTIVEThe phase IIIb A Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Participants With Relapsing Forms of Multiple Sclerosis (VELOCE)…”
Get full text

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study by Bar-Or, Amit, Wiendl, Heinz, Montalban, Xavier, Alvarez, Enrique, Davydovskaya, Maria, Delgado, Silvia R, Evdoshenko, Evgeniy P, Giedraitiene, Natasa, Gross-Paju, Katrin, Haldre, Sulev, Herrman, Craig E, Izquierdo, Guillermo, Karelis, Guntis, Leutmezer, Fritz, Mares, Miroslav, Meca-Lallana, Jose E, Mickeviciene, Dalia, Nicholas, Jacqueline, Robertson, Derrick S, Sazonov, Denis V, Sharlin, Kenneth, Sundaram, Bharathy, Totolyan, Natalia, Vachova, Marta, Valis, Martin, Bagger, Morten, Häring, Dieter A, Ludwig, Inga, Willi, Roman, Zalesak, Martin, Su, Wendy, Merschhemke, Martin, Fox, Edward J

“…Background: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, is approved in several countries for relapsing multiple sclerosis (RMS)…”
Get full text

Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study by Newsome, Scott D, Goldstick, Lawrence, Robertson, Derrick S, Bowen, James D, Naismith, Robert T, Townsend, Ben, Figueiredo, Catarina, Kletzl, Heidemarie, Giraudon, Mylene, Bortolami, Oscar, Zecevic, Dusanka, Giacobino, Caroline, Clinch, Susanne, Shen, Yun-An, Deol-Bhullar, Gurpreet, Bermel, Robert A

“…Subcutaneous ocrelizumab is being developed to provide treatment flexibility and additional choice to patients with multiple sclerosis. OCARINA I (NCT03972306)…”
Get full text